Innate endogenous adjuvants prime to desirable immune responses via mucosal routes

Abstract

Vaccination is an effective strategy to prevent infectious or immune related diseases, which has made remarkable contribution in human history. Recently increasing attentions have been paid to mucosal vaccination due to its multiple advantages over conventional ways. Subunit or peptide antigens are more reasonable immunogens for mucosal vaccination than live or attenuated pathogens, however adjuvants are required to augment the immune responses. Many mucosal adjuvants have been developed to prime desirable immune responses to different etiologies. Compared with pathogen derived adjuvants, innate endogenous molecules incorporated into mucosal vaccines demonstrate prominent adjuvanticity and safety. Nowadays, cytokines are broadly used as mucosal adjuvants for participation of signal transduction of immune responses, activation of innate immunity and polarization of adaptive immunity. Desired immune responses are promptly and efficaciously primed on basis of specific interactions between cytokines and corresponding receptors. In addition, some other innate molecules are also identified as potent mucosal adjuvants. This review focuses on innate endogenous mucosal adjuvants, hoping to shed light on the development of mucosal vaccines.

Keywords

mucosal vaccine / adjuvant / innate endogenous molecules

References

[1] Abraham E, Shah S (1992) Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-speciflc pulmonary secretory antibody-response. J Immunol149: 3719-3726

[2] Arulanandam BP, Metzger DW (1999) Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine17: 252-260

[3] Arulanandam BP, O’Toole M, Metzger DW (1999) Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis180: 940-949

[4] Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW (2001) Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun69: 6718-6724

[5] Baca-Estrada ME, Foldvari M, Snider M (1999) Induction of mucosal immune responses by administration of liposomeantigen formulations and interleukin-12. J Interferon Cytokine Res19: 455-462

[6] Baggiolini M, Dahinden CA (1994) CC chemokines in allergic inflammation. Immunol Today15: 127-133

[7] Baqar S, Pacheco ND, Rollwagen FM (1993) Modulation of mucosal immunity against Campylobacter jejuni by orally-administered cytokines. Antimicrob Agents Chemother37: 2688-2692

[8] Baron SD, Singh R, Metzger DW (2007) Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun75: 2152-2162

[9] Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med192: 1453-1465

[10] Beilharz MW, Cummins MJ, Bennett AL, Cummins JM (2010) Oromucosal administration of interferon to humans. Pharmaceuticals3: 323-344

[11] Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, Guimaraes V, Rabot S, Alcocer-Gonzalez JM, Gratadoux JJ, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G (2005) A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol175: 7297-7302

[12] Bertley FMN, Kozlowski PA, Wang SW, Chappelle J, Patel J, Sonuyi O, Mazzara G, Monteflori D, Carville A, Mansfleld KG (2004) Control of simian/human immunodeflciency virus viremia and disease progression after IL-2-augmented DNA-modifled vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol172: 3745-3757

[13] Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, McGhee JR (1999) IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol162: 122-128

[14] Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, Van Deventer SJH, Neirynck S, Peppelenbosch MP, Steidler L (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol4: 754-759

[15] Bracci L, Canini I, Puzelli S, Sestili P, Venditti M, Spada M, Donatelli I, Belardelli F, Proietti E (2005) Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine23: 2994-3004

[16] Bracci L, Canini I, Venditti M, Spada M, Puzelli S, Donatelli I, Belardelli F, Proietti E (2006) Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine24: S56-S57

[17] Bracci L, La Sorsa V, Belardelli F, Proietti E (2008) Type I interferons as vaccine adjuvants against infectious diseases and cancer. Expert Rev Vaccines7: 373-381

[18] Braciak TA, Gallichan WS, Graham FL, Richards CD, Ramsay AJ, Rosenthal KL, Gauldie J (2000) Recombinant adenovirus vectors expressing interleukin-5 and-6 speciflcally enhance mucosal immunoglobulin A responses in the lung. Immunology101: 388-396

[19] Bradney CP, Sempowski GD, Liao HX, Haynes BF, Staats HF (2002) Cytokines as adjuvants for the induction of anti-human immunodeflciency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol76: 517-524

[20] Brogden KA, Heidari M, Sacco RE, Palmquist D, Guthmiller JM, Johnson GK, Jia HP, Tack BF, McCray PB (2003) Defensininduced adaptive immunity in mice and its potential in preventing periodontal disease. Oral Microbiol Immunol18: 95-99

[21] Bukreyev A, Belyakov IM, Berzofsky JA, Murphy BR, Collins PL (2001) Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigenpresenting cells. J Virol75: 12128-12140

[22] Cao M, Sasaki O, Yamada A, Imanishi J (1992) Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. Vaccine10: 238-242

[23] Chodaczek G, Zimecki M, Lukasiewicz J, Lugowski C (2006) A complex of lactoferrin with monophosphoryl lipid A is an efflcient adjuvant of the humoral and cellular immune response in mice. Med Microbiol Immunol195: 207-216

[24] Chun S, Daheshia M, Lee S, Eo SK, Rouse BT (1999) Distribution fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10. J Immunol163: 2393-2402

[25] Couch RB, Atmar RL, Cate TR, Quarles JM, Keitel WA, Arden NH, Wells J, Nino D, Wyde PR (2009) Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine27: 5344-5348

[26] Cox E, Verdonck F, Vanrompay D, Goddeeris B (2006) Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res37: 511-539

[27] De Magistnis MT (2006) Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev58: 52-67

[28] Degre M, Bukholm G (1995) Orally administered interferon-gamma but not tumor necrosis factor-alpha suppress infection with Salmonella typhimurium in a mouse model. J Biol Regul Homeost Agents9: 15-20

[29] Dinarello CA (2000) Proinflammatory cytokines. Chest118: 503-508

[30] Drexler HG, Quentmeier H (2004) FLT3: receptor and ligand. Growth Factors22: 71-73

[31] Egan MA, Chong SY, Hagen M, Megati S, Schadeck EB, Piacente P, Ma BJ, Monteflori DC, Haynes BF, Israel ZR (2004) A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-speciflc humoral immune responses in cynomolgus macaques. Vaccine22: 3774-3788

[32] Eo SK, Lee S, Chun S, Rouse BT (2001a) Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines. J Virol75: 569-578

[33] Eo SK, Lee S, Kumaraguru U, Rouse BT (2001b) Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine19: 4685-4693

[34] Ferko B, Kittel C, Romanova J, Sereinig S, Katinger H, Egorov A (2006) Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol80: 11621-11627

[35] Fukuiwa T, Sekine S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Krieg AM, McGhee JR (2008) A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine26: 4849-4859

[36] Giudice EL, Campbell JD (2006) Needle-free vaccine delivery. Adv Drug Deliv Rev58: 68-89

[37] Griffln KF, Eyles JE, Spiers ID, Alpar HO, Williamson ED (2002) Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFNgamma or IL-4, but not IL-6. Vaccine20: 3650-3657

[38] Gwinn WM, Kirwan SM, Wang SH, Ashcraft KA, Sparks NL, Doil CR, Tlusty TG, Casey LS, Hollingshead SK, Briles DE (2010) Effective induction of protective systemic immunity with nasally administered vaccines adjuvantedwith IL-1. Vaccine28: 6901-6914

[39] Hanazawa T, Antuni JD, Kharitonov SA, Barnes PJ (2000) Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis. J Allergy Clin Immunol105: 58-64

[40] Hinc K, Stasilojc M, Piatek I, Peszynska-Sularz G, Isticato R, Ricca E, Obuchowski M, Iwanicki A (2014) Mucosal adjuvant activity of IL-2 presenting spores of Bacillus subtilis in a murine model of Helicobacter pylori vaccination. Plos One9: e95187

[41] Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med11: S45-S53

[42] Holmgren J, Czerkinsky C, Eriksson K, Mharandi A (2003) Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine21: S89-S95

[43] Hu K, Luo S, Tong L, Huang X, Jin W, Huang W, Du T, Yan Y, He S, Griffln GE (2013) CCL19 and CCL28 augment mucosal and systemic immune responses to HIV-1 gp140 by mobilizing responsive immunocytes into secondary lymph nodes and mucosal tissue. J Immunol191: 1935-1947

[44] Huber VC, Arulanandam BP, Arnaboldi PM, Elmore MK, Sheehan CE, Kallakury BV, Metzger DW (2003) Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol3: 801-809

[45] Inoue T, Inoue Y, Nakamura T, Yoshida A, Inoue Y, Tano Y, Shimomura Y, Fujisawa Y, Aono A, Hayashi K (2002) The effect of immunization with herpes simplex virus glycoprotein D fused with interleukin-2 against murine herpetic keratitis. Jpn J Ophthalmol46: 370-376

[46] Jang YS, Kim SH, Lee HY, Lee H, Kim J, Kim DH, Lee KY (2013) The cathelicidin LL-37 exerts its mucosal adjuvant activity via enhancing germinal center formation and dendritic cell maturation. J Immunol190: 124

[47] Kalled SL (2006) Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol18: 290-296

[48] Kataoka K, McGhee JR, Kobayashi R, Fujihashi K, Shizukuishi S, Fujihashi K (2004) Nasal Flt3 ligand cDNA elicits CD11c(+)CD8 (+) dendritic cells for enhanced mucosal immunity. J Immunol172: 3612-3619

[49] Kataoka K, Fujihashi K, Oma K, Fukuyama Y, Hollingshead SK, Sekine S, Kawabata S, Ito HO, Briles DE, Oishi K (2011) The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect Immun79: 2819-2828

[50] Kaul D, Ogra PL (1998) Mucosal responses to parenteral and mucosal vaccines. Dev Biol Stand95: 141-146

[51] Kayamuro H, Abe Y, Yoshioka Y, Katayama K, Nomura T, Yoshida T, Yamashita K, Yoshikawa T, Kawai Y, Mayumi T (2009a) The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials30: 5869-5876

[52] Kayamuro H, Yoshioka Y, Abe Y, Katayama K, Yoshida T, Yamashita K, Yoshikawa T, Hiroi T, Itoh N, Kawai Y (2009b) TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochem Biophys Res Commun384: 296-300

[53] Kayamuro H, Abe Y, Yoshioka Y, Katayama K, Yoshida T, Yamashita K, Yoshikawa T, Kawai Y, Mayumi T, Hiroi T (2010a) Mutant TNF-alpha, mTNF-K90R, is a novel candidate adjuvant for a mucosal vaccine against HIV. Pharmazie65: 254-256

[54] Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, Nomura T, Yoshikawa T, Kubota-Koketsu R, Ikuta K, Okamoto S (2010b) Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J Virol84: 12703-12712

[55] Kayamuro H, Yoshioka Y, Abe Y, Katayama K, Arita S, Nomura T, Yoshikawa T, Itoh N, Kamada H, Tsunoda S (2011) Identiflcation of new candidates as mucosal vaccine adjuvant in TNF family cytokines. In: Advances in TNF family research, Springer New York, pp 299-304

[56] Kim HD, Cao YP, Kong FK, Van Kampen KR, Lewis TL, Ma ZD, Tang DCC, Fukuchi KI (2005) Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. Vaccine23: 2977-2986

[57] Kodama S, Hirano T, Noda K, Abe N, Suzuki M (2010) A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-speciflc long-term mucosal immune responses in the nasopharynx. Vaccine28: 2510-2516

[58] Kodama S, Abe N, Hirano T, Suzuki M (2011) A single nasal dose of CCL20 chemokine induces dendritic cell recruitment and enhances nontypable Haemophilus influenzae-speciflc immune responses in the nasal mucosa. Acta Otolaryngol131: 989-996

[59] Kokuryo S, Inoue H, Fukuizumi T, Tsujisawa T, Tominaga K, Fukuda J (2002) Evaluation of interleukin 1 as a mucosal adjuvant in immunization with Streptococcus sobrinus cells by tonsillar application in rabbits. Oral Microbiol Immunol 17: 163-171

[60] Kruzel ML, Zimecki M (2002) Lactoferrin and immunologic dissonance: Clinical implications. Arch Immunol Ther Exp50: 399-410

[61] Lee S, Gierynska M, Eo SK, Kuklin N, Rouse BT (2003) Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbes Infect5: 571-578

[62] Levine MM (2003) Can needle-free administration of vaccines become the norm in global immunization? Nat Med9: 99-103

[63] Lillard JW, Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR (1999a) Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci USA96: 651-656

[64] Lillard JW, Boyaka PN, Hedrick JA, Zlotnik A, McGhee JR (1999b) Lymphotactin acts as an innate mucosal adjuvant. J Immunol162: 1959-1965

[65] Lillard JW, Boyaka PN, Taub DD, McGhee JR (2001) RANTES potentiates antigen-speciflc mucosal immune responses. J Immunol166: 162-169

[66] Lillard JW Jr, Singh UP, Boyaka PN, Singh S, Taub DD, McGhee JR (2003) MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood101: 807-814

[67] Lu Y, Xin KQ, Hamajima K, Tsuji T, Aoki I, Yang J, Sasaki S, Fukushima J, Yoshimura T, Toda S (1999) Macrophage inflammatory protein-1 alpha (MIP-1 alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin Exp Immunol115: 335-341

[68] Lynch JM, Briles DE, Metzger DW (2003) Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun71: 4780-4788

[69] Manrique M, Kozlowski PA, Cobo-Molinos A, Wang SW, Wilson RL, Monteflori DC, Mansfleld KG, Carville A, Aldovini A(2011) Long-term control of simian immunodeflciency virus (mac251) viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeflciency virus DNA/ recombinant modifled vaccinia virus ankara. J Immunol186: 3581-3593

[70] Marinaro M, Boyaka PN, Jackson RJ, Finkelman FD, Kiyono H, Jirillo E, McGhee JR (1999) Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J Immunol162: 114-121

[71] McBride S, Hoebe K, Georgel P, Janssen E (2006) Cell-associated double-stranded RNA enhances antitumor activity through the production of type IIFN. J Immunol177: 6122-6128

[72] Mcghee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H (1992) The mucosal immune system from fundamental concepts to vaccine development. Vaccine10: 75-88

[73] McNeela EA, Mills KHG (2001) Manipulating the immune system: humoral versus cell-mediated immunity. Adv Drug Deliver Rev51: 43-54

[74] Meritet JF, Maury C, Tovey MG (2001) Effect of oromucosal administration of IFN-alpha on allergic sensitization and the hypersensitive inflammatory response in animals sensitized to ragweed pollen. J Interferon Cytokine Res21: 583-593

[75] Mutsch M, Zhou WG, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. New Engl J Med350: 896-903

[76] Namangala B, Inoue N, Kohara J, Kuboki N, Sakurai T, Hayashida K, Sugimoto C (2006) Evidence for the immunostimulatory effects of low-dose orally delivered human IFN-alpha in cattle. J Interferon Cytokine Res26: 675-681

[77] Nambiar JK, Ryan AA, Kong CU, Britton WJ, Triccas JA (2010) Modulation of pulmonary DC function by vaccine-encoded GMCSF enhances protective immunity against Mycobacterium tuberculosis infection. Eur J Immunol40: 153-161

[78] Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA (2001) Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res 61: 6178-6184

[79] Oh YK, Park JS, Yoon H, Kim CK (2003) Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system. Vaccine21: 1980-1988

[80] O’Hagan DT, Rappuoli R (2004) Novel approaches to vaccine delivery. Pharm Res21: 1519-1530

[81] Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishioka K, Fukushima J, Miyazaki J, Wahren B, Okuda K (1997) Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol159: 3638-3647

[82] Pabst R, Luhrmann A, Steinmetz I, Tschernig T (2003) A single intratracheal dose of the growth factor Fms-like tyrosine kinase receptor-3 ligand induces a rapid differential increase of dendritic cells and lymphocyte subsets in lung tissue and bronchoalveolar lavage, resulting in an increased local antibody production. J Immunol171: 325-330

[83] Parker JN, Pflster LA, Quenelle D, Gillespie GY, Markert JM, Kern ER, Whitley RJ (2006) Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine24: 1644-1652

[84] Pockley AG, Montgomery PC (1991) In vivo adjuvant effect of interleukins 5 and 6 on rat tear IgA antibody responses. Immunology73: 19-23

[85] Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, De Vincenzi E, Venditti M, Capone I, Seif I, De Maeyer E (2002) Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol169: 375-383

[86] Ramsay AJ, Kohonencorish M (1993) Interleukin-5 expressed by a recombinant virus vector enhances speciflc mucosal IgA responses in vivo. Eur J Immunol23: 3141-3145

[87] Ramsburg E, Publicover J, Buonocore L, Poholek A, Robek M, Palin A, Rose JK (2005) A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J Virol79: 15043-15053

[88] Sabirov A, Metzger DW (2006) Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine24: 5584-5592

[89] Scheerlinck JPY (2001) Genetic adjuvants for DNA vaccines. Vaccine19: 2647-2656

[90] Sekine S, Kataoka K, Fukuyama Y, Adachi Y, Davydova J, Yamamoto M, Kohayashi R, Fujihashi K, Suzuki H, Curiel DT (2008) A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. J Immunol180: 8126-8134

[91] Shanmugham LN, Petrarca C, Frydas S, Donelan J, Castellani ML, Boucher W, Madhappan B, Tete S, Falasca K, Conti P (2006) IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances. J Exp Clin Cancer Res25: 529-536

[92] Staats HF, Ennis FA (1999) IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J Immunol162: 6141-6147

[93] Staats HF, Bradney CP, Gwinn WM, Jackson SS, Sempowski GD, Liao HX, Letvin NL, Haynes BF (2001) Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J Immunol167: 5386-5394

[94] Steidler L, Robinson K, Chamberlain L, Schofleld KM, Remaut E, Le Page RW, Wells JM (1998) Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun66: 3183-3189

[95] Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science289: 1352-1355

[96] Sui Y, Gagnon S, Dzutsev A, Zhu Q, Yu H, Hogg A, Wang Y, Xia Z, Belyakov IM, Venzon D (2011) TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4(+) memory T cell loss in SIVmac251-challenged rhesus macaques. Vaccine30: 59-68

[97] Sun K, Salmon SL, Lotz SA, Metzger DW (2007) Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect Immun75: 1196-1202

[98] Tertilt C, Joh J, Krause A, Chou PG, Schneeweiss K, Crystal RG, Worgall S (2009) Expression of B-cell activating factor enhances protective immunity of a vaccine against Pseudomonas aeruginosa. Infect Immun77: 3044-3055

[99] Thompson AL, Staats HF (2011) Cytokines: the future of intranasal vaccine adjuvants. Clin Dev Immunol2011: 289597

[100] Thompson AL, Johnson BT, Sempowski GD, Gunn MD, Hou B, DeFranco AL, Staats HF (2012) Maximal adjuvant activity of nasally delivered IL-1 alpha requires adjuvant-responsive CD11c (+) cells and does not correlate with adjuvant-induced in vivo cytokine production. J Immunol188: 2834-2846

[101] Toka FN, Rouse BT (2005) Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity. J Leukoc Biol78: 178-186

[102] Toka FN, Gierynska M, Rouse BT (2003) Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1. J Virol77: 12742-12752

[103] Toka FN, Pack CD, Rouse BT (2004) Molecular adjuvants for mucosal immunity. Immunol Rev199: 100-112

[104] Tovey MG (2002) Oromucosal cytokine therapy: mechanism(s) of action. Taehan Kan Hakhoe Chi8: 125-131

[105] Tovey MG, Maury C (1999) Oromucosal interferon therapy: marked antiviral and antitumor activity. J Interferon Cytokine Res19: 145-155

[106] Tovey MG, Lallemand C, Thyphronitis G (2008) Adjuvant activity of type I interferons. Biol Chem389: 541-545

[107] Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-speciflc adaptive immunity. Annu Rev Immunol13: 251-276

[108] Van Roey GA, Arias MA, Tregoning JS, Rowe G, Shattock RJ (2012) Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol42: 353-363

[109] Vansnick J (1990) Interleukin-6: an overview. Annu Rev Immunol8: 253-278

[110] Walker DM (2004) Oral mucosal immunology: an overview. Ann Acad Med Singap33: 27-30

[111] Wang X, Zhang XY, Kang YM, Jin HL, Du XG, Zhao G, Yu Y, Li JY, Su BW, Huang C (2008) Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine26: 5135-5144

[112] Watanabe Y, Matsumoto Y, Kikuchi R, Kiriyama M, Nakagawa K, Nomura H, Maruyama K, Matsumoto M (1995) Pharmacokinetics and pharmacodynamics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) following intranasal administration in rabbits. J Drug Targ3: 231-238

[113] Watford WT, Moriguchi M, Morinobu A, O’Shea JJ (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev14: 361-368

[114] Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol25: 821-852

[115] Wierzbicki A, Kiszka I, Kaneko H, Kmieciak D, Wasik TJ, Gzyl J, Kaneko Y, Kozbor D (2002) Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. Vaccine20: 1295-1307

[116] Wijesundara DK, Xi Y, Ranasinghe C (2014) Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design. Front Immunol5: 412

[117] Williamson E, Westrich GT, Viney JL (1999) Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol163: 3668-3675

[118] Wright AKA, Christopoulou I, El Batrawy S, Limer J, Gordon SB (2011) rhIL-12 as adjuvant augments lung cell cytokine responses to pneumococcal whole cell antigen. Immunobiology216: 1143-1147

[119] Xin KQ, Hamajima K, Sasaki S, Honsho A, Tsuji T, Ishii N, Cao XR, Lu Y, Fukushima J, Shapshak P (1998) Intranasal administration of human immunodeflciency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cellmediated immunity against HIV-1. Immunology94: 438-444

[120] Xin KQ, Hamajima K, Sasaki S, Tsuji T, Watabe S, Okada E, Okuda K (1999a) IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine17: 858-866

[121] Xin KQ, Lu Y, Hamajima K, Fukushima J, Yang J, Inamura K, Okuda K (1999b) Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-speciflc immunity. Clin Immunol92: 90-96

[122] Xu LY, Yang JS, Huang YM, Levi M, Link H, Xiao BG (2000) Combined nasal administration of encephalitogenic myelin basic protein peptide 68-86 and IL-10 suppressed incipient experimental allergic encephalomyelitis in Lewis rats. Clin Immunol96: 205-211

[123] Zhang X, Yu Q, Zhang X, Yang Q (2009) Co-administration of inactivated avian influenza virus with CpG or rIL-2 strongly enhances the local immune response after intranasal immunization in chicken. Vaccine27: 5628-5632

[124] Zhang HX, Qiu YY, Zhao YH, Liu XT, Liu M, Yu AL (2014) Immunogenicity of oral vaccination with Lactococcus lactis derived vaccine candidate antigen (UreB) of Helicobacter pylon fused with the human interleukin 2 as adjuvant. Mol Cell Probes28: 25-30

[125] Zhou M, Zhang G, Ren G, Gnanadurai CW, Li Z, Chai Q, Yang Y, Leyson CM, Wu W, Cui M (2013) Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations. PLoS One8: e63384

RIGHTS & PERMISSIONS

2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.